Best Diffuse Large B Cell Lymphoma Podcasts (2025)

1
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer 22:14

Play Pause

3d ago22:14

22:14

In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including: Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection The rec…

1
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach 26:01

5d ago26:01

26:01

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including: Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer Results of the phase II REJOICE-Ovarian01 study in patients with platinum-re…

1
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care 35:16

10d ago35:16

35:16

In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including: Trials of neoadjuvant immunotherapies demonstrating remarkable response…

1
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management 27:48

13d ago27:48

27:48

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes …

1
An Homage to the Treg Graft in Allogeneic Transplantation 22:52

18d ago22:52

22:52

In this episode, Shaji Kumar, MD, editor in chief of The Hematologist, and consultant in hematology at Mayo Clinic in Rochester, Minnesota, talks with Robert Negrin, MD, Professor of Medicine at Stanford University and president-elect of ASH. They discuss recent developments in reducing graft versus host disease in allogenic stem cell transplant.…

1
Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer 26:10

27d ago26:10

26:10

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on h…

1
Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer 23:57

27d ago23:57

23:57

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare pro…

1
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options 37:10

28d ago37:10

37:10

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including: Brief overview of BTC and GEA Approved HER2-directed therapies for BTC and GEA and their mechanisms of acti…

1
MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management 1:04:33

1M ago1:04:33

1:04:33

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively impacts patients’ clinical outcomes and quality of life. These …

1
The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations 1:32:45

2M ago1:32:45

1:32:45

| Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face difficulties translating novel and emerging …

1
Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies 54:51

2M ago54:51

54:51

| Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying early signs of DTs, understanding novel systemic therapies like tyrosine …

1
Less Is More: Low-Dose Direct Oral Anticoagulants for Extended Venous Thromboembolism Prophylaxis in Higher-Risk Patients 20:09

2M ago20:09

20:09

In this episode, Contributing Editor Samuel Wilson, MD, talks with Francis Couturaud, MD, PhD, Professor of Pulmonology at University of Brest in France. They discuss low-dose direct oral anticoagulants for extended venous thromboembolism prophylaxis.By The Hematologist

1
Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma 22:53

2M ago22:53

22:53

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the …

1
Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients 13:57

2M ago13:57

13:57

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including: How patients often present with disease-related symptoms Treatment selection considerations for the first-line and second-line setting How to approach palliative care discussions with pa…

1
Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma 16:48

2M ago16:48

16:48

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently u…

1
Emergency Care of Patients with Cancer Receiving CAR T-cell and Bispecific Antibody Immunotherapies Experiencing Serious Adverse Events 47:28

2M ago47:28

47:28

As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present to the emergency room with symptoms of adverse effects (AEs). While T-cell-retargeting therapies have revolutioni…

1
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions 20:20

3M ago20:20

20:20

In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including: Genomic testing options for assessing risk of recurrence Adjuvant treatment duration and holidays with CDK4/6 inhibitors …

1
GATA Lot to Learn: Decoding the Drivers of Down Syndrome-Associated Acute Leukemias 21:13

3M ago21:13

21:13

In this episode, Contributing Editor, Lauren Pommert, MD, MS, leads a conversation with Karen Rabin, MD, PhD, pediatric oncologist at the University of California, San Francisco, and Hans Hitzler, MD, with SickKids Children's Hospital in Toronto. They discuss advances in understanding the disease biology of down syndrome associated acute leukemia. …

1
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas 29:59

3M ago29:59

29:59

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including: The clinical implications of using DLL3 as a therapeutic target The impact of emerging DLL3-targeted therapies on evolving treatment paradigms How to incorpor…

1
Highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting — Driving Knowledge to Action: Building a Better Future 1:30:31

3M ago1:30:31

1:30:31

- Treatment Updates from ASCO 2025 on Lung Cancer- Supportive Care Issues- Treatment Updates from ASCO 2025 on Colorectal Cancer- Quality-of-Life Concerns- Update on Pancreas Cancer- Supportive Care Concerns- Update on Lymphoma- Communicating with Your Health Care Team- Updates on Leukemia from ASCO- Managing Treatment Side Effects- Updates on Mela…

1
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective 24:49

3M ago24:49

24:49

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including: Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules Avail…

1
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025 39:12

3M ago39:12

39:12

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings. Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL ECHO: Rituximab-Bendamustine ±…

1
More Than Medicine: Peer Connection as a Therapeutic Adjunct in Acute Leukemia 22:54

4M ago22:54

22:54

In this episode, Contributing Editor Lori Muffly, MD, MS, leads a conversation with two patients — Matt and Rohan — both of whom have undergone cord blood transplants for their acute myeloid leukemia. They discuss the value of peer connection as a vital component of their leukemia and transplant journey.…

1
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting 35:02

4M ago35:02

35:02

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic brea…

1
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC 18:04

4M ago18:04

18:04

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC: Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs…

1
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors? 22:23

4M ago22:23

22:23

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care. Presenters: Eytan M. Stein, MD Chief, Leukemia Service Director, Program for Drug Development in Leukemia Associate Attending P…

1
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025 21:24

4M ago21:24

21:24

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including: The randomized phase III FLAIR trial The randomized phase III SEQUOIA trial The randomized phase III BRUIN CLL-321 trial Pres…

1
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma 31:19

4M ago31:19

31:19

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including: Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC Overview of the Latest Data for the Combination of …

1
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies 35:36

4M ago35:36

35:36

In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 202…

1
Experts Discuss CELMoDs in Myeloma 35:51

4M ago35:51

35:51

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDs Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma The clinical implicatio…

1
Treating Metastatic HER2-negative Breast Cancer: Oncology Nursing Approaches to Improve Patient Quality of Life 49:37

4M ago49:37

49:37

In this enduring CEC ONS Chapter installment, expert faculty will review emerging data on ADC use for HER2-neg MBC and share insights and strategies on the impact of AEs associated with ADC use and approaches to the management of AEs associated with ADCs in this patient population. To learn more: https://www.ceconcepts.com/activity/treating-metasta…

1
Advancing Cervical Cancer Care: Navigating New Therapies, Guidelines, and Patient-Centric Approaches 48:09

4M ago48:09

48:09

In this CE Concepts Grand Rounds series, expert faculty will examine the evolving treatment landscape for advanced cervical cancer and discuss how they develop individualized treatment plans that apply current guideline recommendations, consider new treatment methods, and respect the unique needs of each patient. Find more details and collect credi…

1
Addressing the LGBTQI+ Health Disparities Gap 56:55

5M ago56:55

56:55

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV- The LGBTQI+ Community’s Disproportionate Cancer Burden- Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers- Barriers to Health Care Access, Including Discrimination- Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housi…

1
Addressing the LGBTQI+ Health Disparities Gap 56:55

4M ago56:55

56:55

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV- The LGBTQI+ Community’s Disproportionate Cancer Burden- Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers- Barriers to Health Care Access, Including Discrimination- Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housi…

1
Children as Caregivers for a Loved One with Cancer 56:06

5M ago56:06

56:06

- Definition of a Caregiver- What Research Tells Us About Children as Caregivers’ Well Being- Children as Caregivers- Children as Caregivers for a Sibling- Children as Caregivers for a Parent- Children as Caregivers for a Grandparent- Children as Caregivers for an Older Adult- Children as Caregivers for a Younger Adult- Children as Caregivers for C…

1
Children as Caregivers for a Loved One with Cancer 56:06

5M ago56:06

56:06

- Definition of a Caregiver- What Research Tells Us About Children as Caregivers’ Well Being- Children as Caregivers- Children as Caregivers for a Sibling- Children as Caregivers for a Parent- Children as Caregivers for a Grandparent- Children as Caregivers for an Older Adult- Children as Caregivers for a Younger Adult- Children as Caregivers for C…

1
Pomalidomide: A Step on the PATH Forward for Treatment of Hereditary Hemorrhagic Telangiectasia 22:00

5M ago22:00

22:00

In this episode, Contributing Editor Surbhi Shah, MBBS, MD, a clinician, researcher, and educator at Mayo Clinic in Phoenix, Arizona, talks with Keith McCrae, MD, director of classical hematology at the Taussig Cancer Institute and professor of molecular medicine at the Cleveland Clinic Lerner College of Medicine in Ohio. They discuss a recent pape…

1
MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-World Applications in NF1-PN Management 1:03:44

5M ago1:03:44

1:03:44

In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider comprehensive interprofessional care plans that include disease monitoring, toxicity managem…

1
Diverse Populations Participating in Decisions About Your Care with Your Health Care Team 1:03:12

5M ago1:03:12

1:03:12

- How Being a Member of Diverse Communities May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects, & Pain Management- What to Expect from Your Relationship with Your Health Care Team: Is Your Health Care Team Providing You with Equitable, Excellent Care- What to Consider When Selecting a Cancer Care Team & Treatme…

1
Diverse Populations Participating in Decisions About Your Care with Your Health Care Team 1:03:12

5M ago1:03:12

1:03:12

- How Being a Member of Diverse Communities May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects, & Pain Management- What to Expect from Your Relationship with Your Health Care Team: Is Your Health Care Team Providing You with Equitable, Excellent Care- What to Consider When Selecting a Cancer Care Team & Treatme…

1
Current Perspectives on the Future of Cancer Research 1:05:29

5M ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
Current Perspectives on the Future of Cancer Research 1:05:29

5M ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

5M ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

5M ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

5M ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 18:31

6M ago18:31

18:31

In this episode, Contributing Editor Scott Furlan, MD, PhD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School i…

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

6M ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
When to STOP Treatment for Immune Thrombocytopenia in Patients Experiencing a Complete Response on Thrombopoietin Receptor Agonists 10:34

6M ago10:34

10:34

In this episode, Contributing Editor Michael Scott, MD, a hematologist at St. Michael’s Hospital in Toronto, Canada, and an assistant professor at the University of Toronto, talks with Marc Michel, MD, MSc, head of the internal medicine and clinical immunology department at Henri Mondor University Hospital in Créteil, France. They talk about long-t…

1
Update on Follicular Lymphoma 51:28

6M ago51:28

51:28

- Overview of Follicular Lymphoma- Treatment Options for Newly Diagnosed- Treatment Options for Relapsed/Refractory Disease- Clinical Trial Updates: How Research Increases Treatment Options- New & Emerging Treatments- Factors that May Affect Treatment Planning- Side Effect Prevention & Management- Tips to Improve Communicating with the Health Care …

1
Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates 1:00:44

6M ago1:00:44

1:00:44

- Overview of Diffuse Large B-Cell Lymphoma- Staging & Grading- Current Standard of Care- Treatment Options for Resistant Disease- New & Emerging Treatment Approaches- The Role of Clinical Trials- How Research Contributes to Treatment Choices- Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain- The Increasing Role of Telehealth/Tele…